Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal - The challenges for diagnosis and treatment

Tropical Medicine and International Health

Volumn 13, Issue 1, 2008, Pages 2-5

  Sundar, Shyam ^a   Mondal, Dinesh ^b   Rijal, Suman ^c   Bhattacharya, Sujit ^d   Ghalib, Hashim ^e   Kroeger, Axel ^e   Boelaert, Marleen ^f   Desjeux, Philippe ^g   Richter Airijoki, Heide ^h   Harms, Gundel ⁱ  

^a BANARAS HINDU UNIVERSITY   (India)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^c B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^d INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^g Institute for OneWorld Health   (France)

^h Financial Systems Development Section   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bangladesh; Diagnosis; Elimination; Implementation research; India; Kala azar; Nepal; Treatment; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY; MILTEFOSINE; PAROMOMYCIN;

ANAPHYLACTIC SHOCK; BANGLADESH; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG FATALITY; EDITORIAL; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; INDIA; INFECTION RATE; INFECTION RISK; INJECTION SITE PAIN; LABORATORY TEST; MALNUTRITION; NEPAL; NEPHROTOXICITY; OTOTOXICITY; POLYMERASE CHAIN REACTION; PREVALENCE; SIDE EFFECT; SKIN ALLERGY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS; VOMITING;

ANIMALS; ANTIPROTOZOAL AGENTS; BANGLADESH; HEALTH POLICY; HUMANS; INDIA; INSECT CONTROL; INSECT VECTORS; LEISHMANIASIS, VISCERAL; NEPAL; PROGRAM DEVELOPMENT; PSYCHODIDAE; RESEARCH;

NASO HEXACANTHUS;

EID: 39449120076     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2007.01974.x     Document Type: Editorial

References (18)

1. Alvar J, Yactao S Bern C (2006) Leishmaniasis and poverty. Trends in Parasitology 22, 552 557.
2. Aparicio P Comments (2007) World Health Organization, First Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Geneva, 9-13 July 2007 (Section 6.5.2).
3. Bern C, Hightower AW, Chowdhury R et al. (2005) Risk factors for kala azar in Bangladesh. Emerging Infectious Diseases 11, 655 662.
4. Bhattacharya SK, Sinha PK, Sundar S et al. (2007) Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. Journal of Infectious Diseases 196, 591 598.
5. Cerf BJ, Jones TC, Sampaio R Teixeira R (1987) Malnutrition as a risk factor for severe visceral leishmaniasis. Journal of Infectious Diseases 168, 986 993. Quoted in : Jha TK (2006) Drug unresponsiveness & combination therapy for kala-azar. The Indian Journal of Medical Research 123, 389 398.
6. Meheus F, Boelaert M, Baltussen R Sundar S (2006) Costs of patient management of visceral leishmaniasis in Muzaffarpur. Tropical Medicine and International Health 2, 1715 1724.
7. Singh SP, Reddy DC, Rai M Sundar S (2006) Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Tropical Medicine and International Health 11, 899 905.
8. Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Tropical Medicine and International Health 6, 849 854.
9. Sundar S Murray HW (2005) Availability of miltefosine for the treatment of kala-azar in India (perspective). Bulletin of the World Health Organization 83, 394 395.
10. Sundar S, Reed SG, Singh VP, Kumar PC Murray HW (1998) Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 351, 563 565.
11. Sundar S, Agrawal G, Madhukar R, Makharia MK Murray HW (2001a) Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. British Medical Journal 323, 419 422.
12. Sundar S, Jha TK, Thakur CP et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347, 1739 1746.
13. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M Murray HW (2004) Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clinical Infectious Diseases 38, 377 383.
14. Sundar S, Maurya R, Singh RK et al. (2006) Rapid, non-invasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of ant-K39 antibody. Journal of Clinical Microbiology 44, 251 253.
15. Sundar S, Singh RK, Bimai SK et al. (2007) Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. Tropical Medicine and International Health 12, 284 289.
16. Sundar S, Jha TK, Thakur CP, Sinha PK Bhattacharya SK (2007a) Injectable paromomycin for visceral leishmaniasis in India. New England Journal of Medicine 356, 2571 2581.
17. TDR (2005) Press release: elimination of kala azar from endemic countries in the South-east Asia region. http://www.who.int/tdr/diseases/leish/ press_release.htm
18. World Health Report (2002) Reducing Risks, Promoting Healthy Life. World Health Organization, Geneva, Switzerland. pp. 186 192.